<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8807448</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1179</journal-id>
<journal-id journal-id-type="nlm-ta">Chem Res Toxicol</journal-id>
<journal-id journal-id-type="iso-abbrev">Chem. Res. Toxicol.</journal-id>
<journal-title-group>
<journal-title>Chemical research in toxicology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-228X</issn>
<issn pub-type="epub">1520-5010</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31625720</article-id>
<article-id pub-id-type="pmc">7162671</article-id>
<article-id pub-id-type="doi">10.1021/acs.chemrestox.9b00335</article-id>
<article-id pub-id-type="manuscript">NIHMS1579617</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Use of Zebrafish in Drug Discovery Toxicology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cassar</surname>
<given-names>Steven</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9409-6714</contrib-id>
<xref ref-type="aff" rid="A1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adatto</surname>
<given-names>Isaac</given-names>
</name>
<xref ref-type="aff" rid="A2">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Freeman</surname>
<given-names>Jennifer L.</given-names>
</name>
<xref ref-type="aff" rid="A3">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gamse</surname>
<given-names>Joshua T.</given-names>
</name>
<xref ref-type="aff" rid="A4">∥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iturria</surname>
<given-names>Iñaki</given-names>
</name>
<xref ref-type="aff" rid="A5">⊥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lawrence</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="A6">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muriana</surname>
<given-names>Arantza</given-names>
</name>
<xref ref-type="aff" rid="A5">⊥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peterson</surname>
<given-names>Randall T.</given-names>
</name>
<xref ref-type="aff" rid="A7">∇</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Van Cruchten</surname>
<given-names>Steven</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3144-1840</contrib-id>
<xref ref-type="aff" rid="A8">○</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zon</surname>
<given-names>Leonard I.</given-names>
</name>
<xref ref-type="aff" rid="A9">◆</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>†</label>Preclinical Safety, AbbVie, North Chicago, Illinois 60064, United States</aff>
<aff id="A2"><label>‡</label>Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, United States</aff>
<aff id="A3"><label>§</label>School of Health Sciences, Purdue University, West Lafayette, Indiana 47907, United States</aff>
<aff id="A4"><label>∥</label>Drug Safety Evaluation, Bristol-Myers Squibb, New Brunswick, New Jersey 08901, United States</aff>
<aff id="A5"><label>⊥</label>Biobide, San Sebastián, Spain 20009</aff>
<aff id="A6"><label>#</label>Aquatic Resources Program, Boston Children’s Hospital, Boston, Massachusetts 02115, United States</aff>
<aff id="A7"><label>∇</label>Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah 84112, United States</aff>
<aff id="A8"><label>○</label>University of Antwerp, Wilrijk 2610, Belgium</aff>
<aff id="A9"><label>◆</label>Stem Cell Program and Division of Hematology/Oncology, Children’s Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Harvard Stem Cell Institute, Stem Cell and Regenerative Biology Department, Harvard University, Boston, Massachusetts 02138, United States</aff>
<author-notes>
<fn fn-type="COI-statement" id="FN1">
<p id="P87">The authors declare the following competing financial interest(s): L.I.Z. is a founder and stockholder of Fate Therapeutics, CAMP4 Therapeutics, and Scholar Rock. He is a consultant for Celularity.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>21</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>16</day>
<month>4</month>
<year>2020</year>
</pub-date>
<volume>33</volume>
<issue>1</issue>
<fpage>95</fpage>
<lpage>118</lpage>
<!--elocation-id from pubmed: 10.1021/acs.chemrestox.9b00335-->
<abstract id="ABS1">
<p id="P1">Unpredicted human safety events in clinical trials for new drugs are costly in terms of human health and money. The drug discovery industry attempts to minimize those events with diligent preclinical safety testing. Current standard practices are good at preventing toxic compounds from being tested in the clinic; however, false negative preclinical toxicity results are still a reality. Continual improvement must be pursued in the preclinical realm. Higher-quality therapies can be brought forward with more information about potential toxicities and associated mechanisms. The zebrafish model is a bridge between in vitro assays and mammalian in vivo studies. This model is powerful in its breadth of application and tractability for research. In the past two decades, our understanding of disease biology and drug toxicity has grown significantly owing to thousands of studies on this tiny vertebrate. This Review summarizes challenges and strengths of the model, discusses the 3Rs value that it can deliver, highlights translatable and untranslatable biology, and brings together reports from recent studies with zebrafish focusing on new drug discovery toxicology.</p>
</abstract>
<abstract abstract-type="graphical" id="ABS2">
<title>Graphical Abstract</title>
<p id="P2">
<graphic orientation="portrait" position="anchor" xlink:href="nihms-1579617-f0001.jpg"></graphic>
</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>